临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Everolimus (RAD001)
中文名称: 依维莫司
CAS号:159351-69-6
分子式: C53H83NO14 分子量: 958.22
产品形式: free base
研发状态: Not yet recruiting
研发用途: High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Anaplastic Astrocytoma; Glioblastoma; Glioblastoma Multiforme; Diffuse Midline Glioma H3 K27M-Mutant; Metastatic Brain Tumor; WHO Grade III Glioma; WHO Grade IV Glioma
研究机构: Nationwide Children''s Hospital; Novartis
研发日期: May 30 2024
研发阶段: Phase 2
Everolimus (RAD001, SDZ-RAD, Afinitor) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.
Montelukast
中文名称:孟鲁司特
CAS号:158966-92-8
分子式: C35H36ClNO3S 分子量: 586.18
产品形式: Free Base
研发状态: Not yet recruiting
研发用途: Acne Vulgaris
研究机构: South Valley University
研发日期: Jun-24
研发阶段: Phase 3
Montelukast(MK0476) is a leukotriene receptor antagonist used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.
Disodium Cromoglycate
中文名称:色甘酸钠
CAS号:15826-37-6
分子式: C23H14O11.2Na 分子量: 512.33
产品形式: Disodium Salt
研发状态: Completed
研发用途: Asthma Exercise-Induced
研究机构: MEDA Pharma GmbH & Co. KG; ClinResearch GmbH; Sanofi; Viatris Inc.
研发日期: Nov-07
研发阶段: Phase 2
Disodium Cromoglycate (Gynazole ,FPL 670 (Cromolyn) Disodium,Cromolyn sodium) is an antiallergic drug with IC50 of 39 μg/mL.
Perifosine (KRX-0401)
中文名称:哌立福新
CAS号:157716-52-4
分子式: C25H52NO4P 分子量: 461.66
产品形式: free base
研发状态: Completed
研发用途: Cancer
研究机构: AEterna Zentaris
研发日期: January 24 2012
研发阶段: Phase 1
Perifosine (KRX-0401, NSC639966, D21266) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Travoprost
中文名称:曲伏前列腺素
CAS号:157283-68-6
分子式: C26H35F3O6 分子量: 500.55
产品形式: free base
研发状态: Completed
研发用途: Glaucoma; Application Site Pigmentation Changes
研究机构: Summa Health System
研发日期: Mar-08
研发阶段: Phase 4
Travoprost (Travoprostum) is a PGF2a analog that was launched as an ophthalmic solution administered topically for the treatment of elevated intraocular hypertension as a result of open-angle glaucoma, a common optic neuropathy, and a leading cause of blindness. It can act as an agonist of prostaglandin F receptor.
Bosentan Hydrate
中文名称:波生坦
CAS号:157212-55-0
分子式: C27H29N5O6S.H2O 分子量: 569.63
产品形式: Hydrate
研发状态: Unknown status
研发用途: Advanced Solid Tumor
研究机构: PharmaMar
研发日期: January 14 2021
研发阶段: Phase 1
Bosentan (Ro 47-0203) is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
